Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

AVBP vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANNX Captures Overall Composite Edge (43.5 HOLD vs 42.8 HOLD), While AVBP Leads 3–1 on Growth & Valuation Pillars

ANNX Overall Winner 6-Pillar Tally: AVBP 3 – 1 ANNX (2 Tie) Matrix Metrics: AVBP 1 – 5 ANNX

As of Nov 17, 2026, Annexon, Inc. (ANNX) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.8/100 HOLD) after splitting the core matrix 5–1 (led by Options & Positioning), while AVBP wins 3–1 across the 6-pillar growth and valuation breakdown. AVBP trades at $10.69 (N/M Forward P/E, -3620.0% operating margin) versus ANNX at $3.47 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ANNX earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. AVBP 42.8/100 HOLD) and 1.70β · 63% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVBP vs ANNX
AVBP NASDAQ
ArriVent BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$10.69
-7.53% 1D
Market Cap $672.9M
TTM Revenue $5.0M
Forward P/E N/M
Beta / 30D Vol 1.35β · 128% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 25.0 Fund 49.0 Flow 68.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.3%), weak momentum, RSI 28
RSI-14: 28.3 · SMA20: $14.60 · SMA50: $20.58
ANNX NASDAQ Head-to-Head Winner
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.47
-2.8% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (AVBP 3 – 1 ANNX)

Columns: Metric · AVBP · ANNX
1. Valuation Multiples AVBP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 111.9x N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.0M N/A
Market Cap $672.9M $747.8M
3. Profitability & Quality AVBP
Gross Margin 100.0% N/A
Operating Margin -3620.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -48.7% -130.8%
4. Balance Sheet & Cash Flow AVBP
Cash Generation (TTM) -$153M -$190M
Cash Flow Margin N/A N/A
Net Cash / Leverage $113M Net Cash $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 119.3% (16th %ile) 569.3% (100th %ile)
Put/Call OI Skew 0.16x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVBP (1) vs ANNX (5)
Institutional Metric AVBP ANNX Criterion Row Edge
Market Capitalization
Scale
$672.9M $747.8M Larger Scale ANNX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-3620.0% 0.0% Higher Margin ANNX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-48.7% -130.8% Higher ROE AVBP
52-Week Range Position
Momentum
1% ($10–$36) 18% ($3–$7) Stronger Trend ANNX
Beta / 30D Volatility
Risk Regime
1.35β · 128% Vol 1.70β · 63% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite ANNX
Trailing 12M Revenue (USD)
Operating Scale
$5.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 111.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$153M ($113M Net Cash) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANNX +26.94 pp
AVBP: -40.41% · ANNX: -13.47%
3M Horizon ANNX +27.48 pp
AVBP: -64.39% · ANNX: -36.91%
6M Horizon ANNX +29.79 pp
AVBP: -59.12% · ANNX: -29.33%
1Y Horizon ANNX +76.37 pp
AVBP: -48.33% · ANNX: +28.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVBP vs ANNX. Trailing 12-month operating profitability (AVBP -3620.0% vs ANNX 0.0%) and valuation multiples (AVBP N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AVBP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.0M
Gross Margin100.0%
Op. Margin-3620.0%
ROE / Fwd P/E-48.7% · N/M
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVBP BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 119.3%
IV Percentile 16th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $672.9M market capitalization and -3620.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVBP vs ANNX Key Questions & Quantitative Answers

As of Nov 17, 2026, Annexon, Inc. (ANNX) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.8/100 HOLD) after splitting the core matrix 5–1 (led by Options & Positioning), while AVBP wins 3–1 across the 6-pillar growth and valuation breakdown. AVBP trades at $10.69 (N/M Forward P/E, -3620.0% operating margin) versus ANNX at $3.47 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ANNX earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. AVBP 42.8/100 HOLD) and 1.70β · 63% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVBP and ANNX split Growth & Scale metrics: AVBP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -3620.0% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AVBP generates $5.0M in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, AVBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

AVBP screens cheaper on headline valuation multiples. AVBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 111.9x EV/Revenue (unreported FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVBP (-48.7% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AVBP carries 119.3% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.35β · 128% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.